MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer von de Leeuw, Renée, McNair, Christopher, Schiewer, Matthew J, Neupane, Neermala Poudel, Brand, Lucas J, Augello, Michael A, Li, Zhen, Cheng, Larry C, Yoshida, Akihiro, Courtney, Sean M, Hazard, E Starr, Hardiman, Gary, Hussain, Maha H, Diehl, J Alan, Drake, Justin M, Kelly, Wm Kevin, Knudsen, Karen E

Volltext

T-Cell redirecting bispecific antibodies: a review of a novel class of immuno-oncology for advanced prostate cancer von Palecki, Julia, Bhasin, Amman, Bernstein, Andrew, Mille, Patrick J., Tester, William J., Kelly, Wm. Kevin, Zarrabi, Kevin K.

Volltext

Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States von Apolo, Andrea B., M.D, Kim, Joseph W., M.D, Bochner, Bernard H., M.D, Steinberg, Seth M., Ph.D, Bajorin, Dean F., M.D, Kevin Kelly, Wm., D.O, Agarwal, Piyush K., M.D, Koppie, Theresa M., M.D, Kaag, Matthew G., M.D, Quinn, David I., M.B.B.S., Ph.D, Vogelzang, Nicholas J., M.D, Sridhar, Srikala S., M.D

Volltext

Enzalutamide: a novel antiandrogen for patients with castrate-resistant prostate cancer von Hoffman-Censits, Jean, Kelly, Wm Kevin

Volltext

Histone deacetylase inhibitors: biology and mechanism of action von Mehnert, Janice M, Kelly, Wm Kevin

Volltext

Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer von Quinn, Zachary, Leiby, Benjamin, Sonpavde, Guru, Choudhury, Atish D, Sweeney, Christopher, Einstein, David, Szmulewitz, Russell, Sartor, Oliver, Knudsen, Karen, Yang, Eddy Shih-Hsin, Kelly, Wm Kevin

Volltext

Pharmacokinetics and Toxicity of Weekly Docetaxel in Older Patients von Hurria, Arti, Fleming, Mark T, Baker, Sharyn D, Kelly, Wm Kevin, Cutchall, Katie, Panageas, Katherine, Caravelli, James, Yeung, Henry, Kris, Mark G, Gomez, Jorge, Miller, Vincent A, D'Andrea, Gabriella, Scher, Howard I, Norton, Larry, Hudis, Clifford

Volltext

New and topics: enfortumab vedotin mechanisms of response and resistance in urothelial cancer – What do we understand so far? von Hoffman-Censits, Jean, Lombardo, Kara, McConkey, David, Hahn, Noah M., Bashir, Babar, Kelly, Wm. Kevin, Johnson, Burles, Matoso, Andres

Volltext

PARP Inhibitors in Prostate Cancer von Ramakrishnan Geethakumari, Praveen, Schiewer, Matthew J., Knudsen, Karen E., Kelly, Wm. Kevin

Volltext

A Randomized Phase II Study of Androgen Deprivation Therapy with or without Palbociclib in RB-positive Metastatic Hormone-Sensitive Prostate Cancer von Palmbos, Phillip L, Daignault-Newton, Stephanie, Tomlins, Scott A, Agarwal, Neeraj, Twardowski, Przemyslaw, Morgans, Alicia K, Kelly, Wm Kevin, Arora, Vivek K, Antonarakis, Emmanuel S, Siddiqui, Javed, Jacobson, Jon A, Davenport, Matthew S, Robinson, Dan R, Chinnaiyan, Arul M, Knudsen, Karen E, Hussain, Maha

Volltext

Prospective Trial of the Herbal Supplement PC-SPES in Patients With Progressive Prostate Cancer von SMALL, Eric J, FROHLICH, Mark W, BOK, Robert, SHINOHARA, Katsuto, GROSSFELD, Gary, ROZENBLAT, Zinovi, KELLY, Wm. Kevin, CORRY, Michele, REESE, David M

Volltext

CCR 20th Anniversary Commentary: Vorinostat-Gateway to Epigenetic Therapy von Kelly, Wm Kevin, Marks, Paul, Richon, Victoria M

Volltext

A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castrat... von Hussain, Maha, Rathkopf, Dana, Liu, Glenn, Armstrong, Andrew, Kelly, Wm. Kevin, Ferrari, Anna, Hainsworth, John, Joshi, Adarsh, Hozak, Rebecca R, Yang, Ling, Schwartz, Jonathan D, Higano, Celestia S

Volltext

Predictors of consenting to participate in a clinical trial among urban cancer patients von McIntire, Russell K., Keith, Scott W., Nowlan, Thomas, Butt, Seif, Cambareri, Katherine, Callaghan, Joseph, Halstead, Tiara, Chandrasekar, Thenappan, Kelly, Wm. Kevin, Leader, Amy E.

Volltext

Phase I clinical trial of histone deacetylase inhibitor: Suberoylanilide hydroxamic acid administered intravenously von KELLY, Wm. Kevin, RICHON, Victoria M, DROBNJAK, Marija, CORDON-CORDO, Carlos, CHIAO, Judy H, RIFKIND, Richard, MARKS, Paul A, SCHER, Howard, O'CONNOR, Owen, CURLEY, Tracy, MACGREGOR-CURTELLI, Barbara, TONG, William, KLANG, Mark, SCHWARTZ, Lawrence, RICHARDSON, Stacie, ROSA, Eddie

Volltext

Substantial Gleason reclassification in Black men with national comprehensive cancer network low-risk prostate cancer – A propensity score analysis von Awasthi, Shivanshu, Mahal, Brandon A., Park, Jong Y., Creed, Jordan H., Williams, Vonetta L., Elkenawi, Asmaa, Meadows, Sylvester O., Pow-Sang, Julio M., Lu-Yao, Grace, Kelly, Wm. Kevin, Lang, Damaris-Lois Y., Zgibor, Janice, Rebbeck, Timothy R., Yamoah, Kosj

Volltext

Targeting Epigenetics for the Treatment of Prostate Cancer: Recent Progress and Future Directions von Lin, Jianqing, Wang, Chenguang, Kelly, Wm. Kevin

Volltext

STEAP1 as a potential target for new therapies in prostate cancer von Kelly, Wm Kevin

Volltext

Perspectives on Adjuvant Therapy in Renal Cell Carcinoma von Mark, J Ryan, Gomella, Leonard G, Kelly, Wm Kevin

Volltext

Prostate Cancer, Comorbidity, and Participation in Randomized Controlled Trials of Therapy von Chao, Herta H., Mayer, Tina, Concato, John, Rose, Michal G., Uchio, Edward, Kelly, Wm. Kevin

Volltext